ClinicalTrials.gg
WithdrawnNCT04563195BAFF/IL-17Updated Jan 27, 2022

BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome

A Phase 2/3 interventional study of tibulizumab (LY3090106) in Primary Sjogren's Syndrome, sponsored by Matthew C. Baker. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-01-27.

Sponsored by Matthew C. Baker · Phase 2/3, Interventional, and Treatment

How we know

Why this study was withdrawn
Drug unavailable

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.

Enrollment
74th of 76
0 · median 57
Started
2022
with 2 others
Phase 2/3
2 of 111
none open now
Registered
73rd of 111
by date

Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 74th largest by enrollment of the 76 interventional ones that give a count, is one of 3 that started in 2022, is one of 2 in phase 2/3, and was the 73rd registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Sjogren's Syndrome with a site in United States, or all of them as a file.
02

Study summary

To demonstrate that tibulizumab (LY3090106) treatment improves the mean unstimulated salivary flow rate or the salivary gland total ultrasound score (TUS) in primary Sjogren's syndrome patients at week 12 compared to the baseline visit.

Read the detailed description

This will be a single-site, open-label study in patients with primary Sjogren's syndrome. All patients will receive tibulizumab (LY3090106) 300mg subcutaneously every 2 weeks for a total of 12 weeks.

Primary Sjogren's syndrome was selected as a relevant patient population based on the mechanism of action of the molecule and the current understanding of the pathogenesis of the disease. An open-label design was chosen based on practical considerations regarding the number of patients that could be recruited. Although open-label studies are subject to bias, objective primary endpoints were intentionally chosen to minimize this concern.

The goal of this study is to demonstrate that tibulizumab (LY3090106) treatment improves the mean unstimulated salivary flow rate or the salivary gland total ultrasound score (TUS) in primary Sjogren's syndrome patients at week 12 compared to the baseline visit.

03

Conditions studied

  • Primary Sjogren's Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women 18-85 years of age
  • Confirmed diagnosis of primary Sjogren's syndrome by the 2016 ACR-EULAR classification criteria for primary Sjogren's syndrome
  • All women (regardless of ) must test negative for pregnancy at the time of screening
  • Women must also agree to use a reliable method of from screening until 12 weeks following last dose of study drug unless they are not of child bearing potential
  • Have stimulated whole salivary flow rate of greater than or equal to 0.10 ml/minute
  • Have a salivary gland total ultrasound score (TUS) of less than or equal to 9 (on a 0-11 point scale)

Exclusion criteria

Exclusion Criteria:

  • Currently enrolled in a clinical trial involving an product or off-label use of a drug
  • Concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have received any nonbiologic investigational product within 30 days or 5 half-lives (whichever is longer) of their baseline (Day 1) visit
  • Have received any biologic investigational product within 3 months or 5 half-lives (whichever is longer) of their baseline visit, or any leukocyte depleting agent within 12 months of baseline
  • Have disease-modifying antirheumatic drug (DMARD) or use as follows:

    • ANY treatment with a janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, upadacitinib, or filgotinib) within 28 days prior to baseline or planned treatment with a JAK inhibitor during the study
    • UNSTABLE PRESCRIBED DOSE of other synthetic DMARDs (eg, hydroxychloroquine, methotrexate, leflunomide, or sulfasalazine) within 28 days prior to baseline or if the dose of drug is planned to be increased during the study (stable prescriptions are allowed)
    • ANY treatment with cytotoxic or immunosuppressive drugs including but not limited to cyclophosphamide, mycophenolic acid, azathioprine, cyclosporine, sirolimus, or tacrolimus within 28 days prior to screening or planned treatment during the study
    • Have had treatment with biologic DMARDs as follows: Etanercept, adalimumab, or anakinra \<4 weeks before baseline or planned treatment during the study
    • Have had treatment with biologic DMARDs as follows: Infliximab, certolizumab pegol, golimumab, abatacept, or tocilizumab \<8 weeks before baseline or planned treatment during the study
  • Are persons who have previously completed or withdrawn from this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Other
    open label

    open label study; all subjects will receive the same drug at the same dose

    Drug: tibulizumab (LY3090106)

Interventions

  • DrugTibulizumabStudies of TibulizumabTibulizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks

    Also known as: open label

06

What researchers measure

Primary outcomes

  1. whole unstimulated sialometry

    change in unstimulated salivary flow

    Time frame: baseline

  2. whole unstimulated sialometry

    change in unstimulated salivary flow

    Time frame: week 12

  3. salivary gland ultrasound

    change in salivary gland ultrasound score

    Time frame: baseline

  4. salivary gland ultrasound

    change in salivary gland ultrasound score

    Time frame: week 12

Secondary outcomes

  1. ESSDAI

    change in the ESSDAI disease activity score The EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is a physician administered questionnaire containing 12 organ-specific domains designed to measure disease activity. The ESSDAI score is obtained by addition of the twelve domain scores. Each domain score is obtained by multiplying the activity level with the domain weight. The maximum theoretical ESSDAI score is 123 and the minimum score is 0. A higher score means more disease activity (worse outcome).

    Time frame: baseline

  2. ESSDAI

    change in the ESSDAI disease activity score The EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is a physician administered questionnaire containing 12 organ-specific domains designed to measure disease activity. The ESSDAI score is obtained by addition of the twelve domain scores. Each domain score is obtained by multiplying the activity level with the domain weight. The maximum theoretical ESSDAI score is 123 and the minimum score is 0. A higher score means more disease activity (worse outcome).

    Time frame: week 12

  3. ESSPRI

    change in the ESSPRI disease activity score The EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) is a patient completed questionnaire to assess subjective patient symptoms, which includes 3 domains (dryness, fatigue, and pain). The ESSPRI score is calculated by averaging the three domains with a maximum severity score of 10 and minimum score of 0. A higher score means more disease activity (worse outcome).

    Time frame: baseline

  4. ESSPRI

    change in the ESSPRI disease activity score The EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) is a patient completed questionnaire to assess subjective patient symptoms, which includes 3 domains (dryness, fatigue, and pain). The ESSPRI score is calculated by averaging the three domains with a maximum severity score of 10 and minimum score of 0. A higher score means more disease activity (worse outcome).

    Time frame: week 12

  5. whole stimulated sialometry

    change in stimulated salivary flow rate

    Time frame: baseline

  6. whole stimulated sialometry

    change in stimulated salivary flow rate

    Time frame: week 12

  7. Schirmer I test

    change in the Schirmer I test

    Time frame: baseline

  8. Schirmer I test

    change in the Schirmer I test

    Time frame: week 12

  9. MRI

    change in MRI (parenchymal architecture scored 0 to 4 and sialography scored 0 to 4)

    Time frame: baseline

  10. MRI

    change in MRI (parenchymal architecture scored 0 to 4 and sialography scored 0 to 4)

    Time frame: week 12

  11. PET

    change in PET (parotid and submandibular gland SUVmax)

    Time frame: baseline

  12. PET

    change in PET (parotid and submandibular gland SUVmax)

    Time frame: week 12

07

Study locations

1 site
  • Stanford University
    Palo Alto, California 94304, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2022; primary completion for Dec 2023, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2020
First posted
Sep 24, 2020
StartEst.
Feb 1, 2022
Primary completionEst.
Dec 2023
CompletionEst.
Jan 2025
Last update
Jan 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04563195
Lead sponsor
Matthew C. Baker
Responsible party
Matthew C. Baker (Clinical Assistant Professor, Stanford University) — Sponsor-investigator
First posted
Sep 24, 2020
Start date
Feb 1, 2022 (estimated)
Primary completion
Dec 2023 (estimated)
Completion
Jan 2025 (estimated)
Last update
Jan 27, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tibulizumab

Start the discussion